Coming Soon: Second Booster Dose for Select COVID-19 Vaccines

Originally published April 14, 2022
Updated June 16, 2022
Note: This article was updated on June 16, 2022. Updated content is demonstrated with a plus (+) sign.

Effective for dates of service (DOS) on or after March 29, 2022, the U.S. Food and Drug Administration (FDA) amended the Emergency Use Authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine and Moderna COVID-19 vaccine, to allow for use of a second booster dose, to be administered at least four months after initial booster dose, to the following groups for each respective vaccine:

Pfizer-BioNTech:

  • Individuals 12 years of age or older with certain kinds of immunocompromise. This includes individuals who have undergone solid organ transplantation, or who are living with conditions that are considered to have an equivalent level of immunocompromise.

  • Individuals 50 years of age and older.

Moderna:

  • Individuals 18 years of age or older with certain kinds of immunocompromise. This includes individuals who have undergone solid organ transplantation, or who are living with conditions that are considered to have an equivalent level of immunocompromise.

  • Individuals 50 years of age and older.

Providers may now submit claims for second booster dose administration.

+ Additionally, the FDA authorized a booster dose formulation (50 mcg/0.5 ml) of the Moderna COVID-19 booster vaccine. Providers administering a booster dose (regardless of administration sequence) using this new formulation are required to submit a new CPT® administration code when billing Medi-Cal: CPT code 0094A. A booster dose of any manufacturer cannot be billed for the same recipient more than once on the same DOS.

For the most current information regarding Medi-Cal’s COVID-19 response, see the COVID-19 Medi-Cal Response page on the Medi-Cal Provider website.